<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547677</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000571611</org_study_id>
    <secondary_id>SCCC-062004-005</secondary_id>
    <nct_id>NCT00547677</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery for Patients With Hepatic Metastases.</brief_title>
  <official_title>A Phase I Trial of Stereotactic Radiosurgery for Patients With Hepatic Metastases (SBRT Liver)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and&#xD;
      cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic&#xD;
      radiosurgery in treating patients with liver metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerated dose of fractionated stereotactic radiosurgery in&#xD;
           patients with hepatic metastases.&#xD;
&#xD;
        -  To determine the dose-limiting toxicity of stereotactic radiosurgery in these patients.&#xD;
&#xD;
        -  To assess the tumor response in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 3-5 fractions of stereotactic radiosurgery over 14 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 9-13 patients receive escalating doses of stereotactic radiosurgery until 60 Gy is&#xD;
      reached or the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which &gt; 33% of patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 6 weeks, every 3 months for 1&#xD;
      year, every 6 months for 2 years, and then annually for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of stereotactic radiosurgery as assessed by NCI CTCAE v3.0</measure>
  </primary_outcome>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary cancer&#xD;
&#xD;
               -  Stage IV primary disease with up to five liver metastases that are visualized on&#xD;
                  CT scan, MRI of the abdomen, or positron-emission tomography&#xD;
&#xD;
                    -  No liver metastases secondary to germ cell tumor or hematologic malignancy&#xD;
&#xD;
                    -  Other sites of metastases allowed&#xD;
&#xD;
          -  No malignant ascites&#xD;
&#xD;
          -  The cumulative total dose of radiotherapy to ≥ 2/3 of the liver and surrounding normal&#xD;
             tissues, including the esophagus, stomach, and small bowel, must be ≤ 15 Gy&#xD;
&#xD;
          -  Percutaneous or laparoscopic biopsy of the metastasis and placement of 3-5 fiducials&#xD;
             required if undergoing Cyberknife for treatment delivery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Albumin ≥ 3 g/dL&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 1.5 times ULN&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  Prothrombin time &lt; 1.5 times ULN&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  ANC &gt; 1,000/mm³&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of diagnosed inflammatory bowel disease, such as ulcerative colitis or&#xD;
             Crohn's disease&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No hepato-renal syndrome&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior systemic therapy allowed provided complete blood cell counts have recovered&#xD;
&#xD;
          -  No other concurrent antineoplastic treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D. Timmerman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <keyword>liver metastases</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

